Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model

Fig. 7

Summary of data of our IL-15 70Z/3 leukemia mouse model. Injection of IL-15sol-secreting leukemia cells leads to an intraperitoneal expansion of CD4+ and CD8+ T-cells within 7-8 days. The resulting adaptive immune response leads to long-lasting immunity and survival of the host. Injection of IL-15Rc-secreting leukemia cells leads to the massive intraperitoneal expansion of NK1.1+ cells within 7-8 days. The resulting innate-like immune response leads to the quick but incomplete killing of leukemia cells, which eventually results in a relapse, wide-spread disease, and thus the lack of long-lasting immunity and survival

Back to article page